DOGWOOD THERAPEUTICS INC (DWTX) Stock Price & Overview

NASDAQ:DWTXUS92829J2033

Current stock price

1.98 USD
-0.1 (-4.81%)
At close:
3 USD
+1.02 (+51.52%)
After Hours:

The current stock price of DWTX is 1.98 USD. Today DWTX is down by -4.81%. In the past month the price decreased by -30.53%. In the past year, price decreased by -64.89%.

DWTX Key Statistics

52-Week Range1.9431 - 9.5
Current DWTX stock price positioned within its 52-week range.
1-Month Range1.9431 - 3.5
Current DWTX stock price positioned within its 1-month range.
Market Cap
65.934M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-20.25
Dividend Yield
N/A

DWTX Stock Performance

Today
-4.81%
1 Week
-34.00%
1 Month
-30.53%
3 Months
-51.35%
Longer-term
6 Months -64.13%
1 Year -64.89%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

DWTX Stock Chart

DOGWOOD THERAPEUTICS INC / DWTX Daily stock chart

DWTX Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to DWTX. When comparing the yearly performance of all stocks, DWTX is a bad performer in the overall market: 95.89% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

DWTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to DWTX. While DWTX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

DWTX Earnings

Next Earnings DateMar 30, 2026
Last Earnings DateNov 6, 2025
PeriodQ3 / 2025
EPS Reported-$8.20
Revenue Reported
EPS Surprise -556.26%
Revenue Surprise %

DWTX Forecast & Estimates

8 analysts have analysed DWTX and the average price target is 19.38 USD. This implies a price increase of 878.79% is expected in the next year compared to the current price of 1.98.


Analysts
Analysts82.5
Price Target19.38 (878.79%)
EPS Next Y-58.18%
Revenue Next YearN/A

DWTX Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

DWTX Financial Highlights

Over the last trailing twelve months DWTX reported a non-GAAP Earnings per Share(EPS) of -20.25. The EPS decreased by -209.16% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-39.98M
Industry RankSector Rank
PM (TTM) N/A
ROA -43.46%
ROE -51.66%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-300%
Sales Q2Q%N/A
EPS 1Y (TTM)-209.16%
Revenue 1Y (TTM)N/A

DWTX Ownership

Ownership
Inst Owners11.09%
Shares33.30M
Float8.25M
Ins Owners0.01%
Short Float %0.68%
Short Ratio1.22

About DWTX

Company Profile

DWTX logo image Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).

Company Info

IPO: 2020-12-17

DOGWOOD THERAPEUTICS INC

44 Milton Avenue

Alpharetta GEORGIA US

Employees: 12

DWTX Company Website

DWTX Investor Relations

Phone: 18666208655

DOGWOOD THERAPEUTICS INC / DWTX FAQ

What does DOGWOOD THERAPEUTICS INC do?

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. The company is headquartered in Alpharetta, Georgia and currently employs 12 full-time employees. The company went IPO on 2020-12-17. The Company’s research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, Nav 1.7 analgesic program is centered on its lead development candidate, Halneuron, which is a specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (CINP). The Company’s antiviral program includes IMC-1 and IMC-2, which are fixed-dose combinations of nucleoside analog, anti-herpes antivirals and the anti-inflammatory agent celecoxib for the treatment of fibromyalgia (FM) and Long-COVID (LC).


What is the stock price of DOGWOOD THERAPEUTICS INC today?

The current stock price of DWTX is 1.98 USD. The price decreased by -4.81% in the last trading session.


What is the dividend status of DOGWOOD THERAPEUTICS INC?

DWTX does not pay a dividend.


How is the ChartMill rating for DOGWOOD THERAPEUTICS INC?

DWTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the GICS sector and industry of DWTX stock?

DOGWOOD THERAPEUTICS INC (DWTX) operates in the Health Care sector and the Biotechnology industry.


How many employees does DOGWOOD THERAPEUTICS INC have?

DOGWOOD THERAPEUTICS INC (DWTX) currently has 12 employees.


What is DOGWOOD THERAPEUTICS INC worth?

DOGWOOD THERAPEUTICS INC (DWTX) has a market capitalization of 65.93M USD. This makes DWTX a Micro Cap stock.